Couldn’t make it to #ASH25? No worries, we’ve got you covered! Join us at #NashvilleHeme26 on Feb 26–28, 2026, for the latest updates and practice-changing data. We’re offering FREE REGISTRATION for a limited time. Use promo code FREECME today! https://t.co/bLnTDjxv7s

What a great evening at the @IDEOlogyHealth social media poll event at #SABCS25 with an excellent group of breast oncologists—and our very own breast surgeon Kristin Rojas. An amazing moment to learn and work through complicated, very new data and how to apply it in real-world

Fantastic @IDEOlogyHealth social media poll event tonight with a fantastic group of friends. I know they helped me clarify my thoughts on a lot of complicated very new data and how to integrate it all into my clinical practice. #SABCS25

IDEO Xchange: With multiple oral SERDs emerging for ESR1-mutated mBC, what excites you most about evolving landscape?

IDEO Xchange: SERENA-6: Switching to camizestrant + CDK4/6i atESR1m detection delayed QoL decline (23.0 vs 6.4 mo vs AI). How impactful are these PRO findings on your treatment decisions?

IDEO Xchange: TROPION-Breast02: Dato-DXd in 1L mTNBC showed strong efficacy (PFS, OS, response rates). How practice-changing are these results?

IDEO Xchange: Which trial shows greater clinical impact?​ 🔹 DESTINY-Breast11: T-DXd ± THP improved pCR vs ddAC-THP​ 🔹 DESTINY-Breast05: T-DXd cut IDFS risk by 53% vs T-DM1

IDEO Xchange: DESTINY-Breast05: T-DXd cut recurrence/death risk by 53% vs T-DM1 & raised 3-yr IDFS to 92.4% vs 83.7%. How practice-changing is this for high-risk HER2+ eBC?

IDEO Xchange: DESTINY-Breast11: T-DXd+THP achieved pCR 67.3% vs 56.3% with ddAC-THP (RCB 0/I: 81.3% vs 69.1%). If approved, how likely are you to adopt this regimen in practice?

Join us live on X tonight at 9:30 pm Central for our IDEO Xchange discussing the latest developments in #breastcancer with Drs. @Dr_RShatsky @hoperugo @AbiSivaMD @mabelonc @DrWGradishar @MeganKruseMD @gandhi_shipra @dougmarksmd @Neil_Iyengar @kristinrojasmd @NinaOncMD

Hear from the renowned Dr. @CairoMichelina as she shares key insights on the role of ribociclib in early HR+/HER2− breast cancer in this quick 1-minute #SoundBites video. A must-watch from one of the field’s leading experts. Register for free to watch now:

Great news! @DrKrinaPatel is joining the faculty for the 2-day CE-accredited Nashville Hematology Conference! World-class CAR-T & myeloma expertise + that legendary energy = sessions you do NOT want to miss. We’re offering FREE REGISTRATION for a limited time to #NashvilleHeme26

We’re doing something special this year! For the first time ever, we’re offering FREE REGISTRATION for a limited time to the 2-day CE-accredited Texas Lung Cancer Conference in Austin, TX. Come learn from 100+ world-class faculty and connect with the lung cancer community. You

We’ve never done this before! In appreciation of the healthcare providers who helped us earn “Most Innovative Meeting of 2025,” we’re offering FREE REGISTRATION for a limited time to the 2-day CE-accredited #NashvilleHeme26. Use promo code FREECME and join 60+ faculty in Music

THANK YOU to our incredible faculty for such a thoughtful discussion and memorable Xchange. We are so grateful for what you do each day for patients!

IDEO Xchange: How would you sequence HER2-directed therapies in a patient with mNSCLC?

IDEO Xchange: What is your preferred 1L therapy for a patient with mNSCLC with PD-L1 20% and STK11 and KEAP1 mutations?

IDEO Xchange: When a patient with non-AGA NSCLC develops oligoprogressive disease on systemic therapy, what is your usual approach?

IDEO Xchange: FLAURA2 poor prognosis subgrp data indicate OS benefit across baseline CNS/bone/liver mets and adverse EGFR/TP53 profiles. ​ ​ How likely are you to use osi+chemo as 1L standard for these pts?

IDEO Xchange: What’s your preferred approach to treatmentintensification for 1L EGFR+ NSCLC?